TP53 and ovarian carcinoma: Germline mutations in TP53 also confer significantly increased risk for hereditary breast cancer in the context of the Li Fraumeni syndrome and Li Fraumeni-like syndrome families, however the overall contribution is less than that observed for BRCA1 and BRCA2, as was also shown in a recent study of French Canadian breast and/or ovarian cancer families [25].